Mats Karlsson

Publikationer

Senaste publikationer

• Comparison of Two Methods for Determining Item Characteristic Functions and Latent Variable Time-Course for Pharmacometric Item Response Models (2024)
• Characterization of anti-drug antibody dynamics using a bivariate mixed hidden-markov model by nonlinear-mixed effects approach (2024)
• Model-Informed Precision Dosing to Reduce Vincristine-Induced Peripheral Neuropathy in Pediatric Patients (2024)
• Properties of the full random-effect modeling approach with missing covariate data (2024)
• Predicting the Long-Term Effects of Therapeutic Neutralization of Oncostatin M on Human Hematopoiesis (2024)

Alla publikationer

Artiklar

• Comparison of Two Methods for Determining Item Characteristic Functions and Latent Variable Time-Course for Pharmacometric Item Response Models (2024)
• Characterization of anti-drug antibody dynamics using a bivariate mixed hidden-markov model by nonlinear-mixed effects approach (2024)
• Model-Informed Precision Dosing to Reduce Vincristine-Induced Peripheral Neuropathy in Pediatric Patients (2024)
• Properties of the full random-effect modeling approach with missing covariate data (2024)
• Predicting the Long-Term Effects of Therapeutic Neutralization of Oncostatin M on Human Hematopoiesis (2024)
• Evaluation of covariate effects in item response theory models (2024)
• Training the next generation of pharmacometric modelers (2023)
• Association between Sports Participation, Factor VIII Levels and Bleeding in Hemophilia A (2023)
• Relationship between factor VIII levels and bleeding for rFVIII-SingleChain in severe hemophilia A (2023)
• Optimization of blood pressure measurement practices for pharmacodynamic analyses of tyrosine-kinase inhibitors (2023)
• Generation and application of avatars in pharmacometric modelling (2023)
• Comparison of Seven Non-Linear Mixed Effect Model-Based Approaches to Test for Treatment Effect (2023)
• Evaluation of the effect of erenumab on migraine-specific questionnaire in patients with chronic and episodic migraine (2023)
• Assessment of ibrutinib scheduling on leukocyte, lymph node size and blood pressure dynamics in chronic lymphocytic leukemia through pharmacokinetic-pharmacodynamic models (2023)
• A multistate modeling and simulation framework to learn dose-response of oncology drugs (2023)
• Joint longitudinal model-based meta-analysis of FEV₁ and exacerbation rate in randomized COPD trials (2023)
• Multistate Pharmacometric Model to Define the Impact of Second-Line Immunotherapies on the Survival Outcome of the IMpower131 Study (2023)
• A 12-gene pharmacogenetic panel to prevent adverse drug reactions (2023)
• How to Analyze Continuous and Discrete Repeated Measures in Small-Sample Cross-Over Trials? (2023)
• Ceftriaxone dosing based on the predicted probability of augmented renal clearance in critically ill patients with pneumonia (2022)
• Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab (2022)
• Improved Confidence in a Confirmatory Stage by Application of Item-Based Pharmacometrics Model (2022)
• Population Pharmacokinetic and Concentration-QTc Analysis of Delamanid in Pediatric Participants with Multidrug-Resistant Tuberculosis (2022)
• Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline (2022)
• Assessing Prolongation of the Corrected QT Interval with Bedaquiline and Delamanid Coadministration to Predict the Cardiac Safety of Simplified Dosing Regimens (2022)
• An introduction of the full random effects model (2022)
• Characterizing Absorption Properties of Dispersible Pretomanid Tablets Using Population Pharmacokinetic Modelling (2022)
• Assessing Treatment Effects with Pharmacometric Models (2021)
• Detecting placebo and drug effects on Parkinson's disease symptoms by longitudinal item-score models (2021)
• Pharmacokinetics and safety of high-dose rifampicin in children with TB (2021)
• A Time-to-Event Model Relating Integrated Craving to Risk of Smoking Relapse Across Different Nicotine Replacement Therapy Formulations (2021)
• Multistate model for pharmacometric analyses of overall survival in HER2-negative breast cancer patients treated with docetaxel (2021)
• A general model for cell death and biomarker release from injured tissues (2021)
• Improved Decision-Making Confidence Using Item-Based Pharmacometric Model (2021)
• Bounded Integer Modeling of Symptom Scales Specific to Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia (2021)
• Pharmacometrics-Based Considerations for the Design of a Pharmacogenomic Clinical Trial Assessing Irinotecan Safety (2021)
• Model-Informed Drug Development for Long-Acting Injectable Products (2021)
• Population repeated time-to-event analysis of exacerbations in asthma patients (2021)
• Exposure–safety analysis of QTc interval and transaminase levels following bedaquiline administration in patients with drug‐resistant tuberculosis (2021)
• Improved numerical stability for the bounded integer model (2021)
• Comparison of Precision and Accuracy of Five Methods to Analyse Total Score Data (2021)
• An Item Response Theory-Informed Strategy to Model Total Score Data from Composite Scales (2021)
• Relationship between factor VIII activity, bleeds and individual characteristics in severe hemophilia A patients (2020)
• Performance of longitudinal item response theory models in shortened or partial assessments. (2020)
• Prediction of exposure-driven myelotoxicity of continuous infusion 5-fluorouracil by a semi-physiological pharmacokinetic-pharmacodynamic model in gastrointestinal cancer patients (2020)
• Comparison of covariate selection methods with correlated covariates (2020)
• The effect of food on the pharmacokinetics of oral ivermectin (2020)
• Relating Nicotine Plasma Concentration to Momentary Craving Across Four Nicotine Replacement Therapy Formulations (2020)
• A longitudinal item response model for Aberrant Behavior Checklist (ABC) data from children with autism (2020)
• Item Response Theory Modeling of the International Prostate Symptom Score in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia (2020)
• Comparing Circulating Tumor Cell Counts with Dynamic Tumor Size Changes as Predictor of Overall Survival (2020)
• Understanding the drug exposure-response relationship of bedaquiline to predict efficacy for novel dosing regimens in the treatment of multidrug-resistant tuberculosis (2020)
• Generating evidence for precision medicine (2020)
• Handling interoccasion variability in model-based dose individualization using therapeutic drug monitoring data (2019)
• Bayesian Forecasting Utilizing Bleeding Information to Support Dose Individualization of Factor VIII (2019)
• Development of visual predictive checks accounting for multimodal parameter distributions in mixture models (2019)
• Handling underlying discrete variables with bivariate mixed hidden Markov models in NONMEM (2019)
• Sensitivity of Pegfilgrastim Pharmacokinetic and Pharmacodynamic Parameters to Product Differences in Similarity Studies (2019)
• Sensitivity of Pegfilgrastim Pharmacokinetic and Pharmacodynamic Parameters to Product Differences in Similarity Studies (2019)
• Population pharmacokinetics of oral ivermectin in venous plasma and dried blood spots in healthy volunteers (2019)
• A Novel Method for Analysing Frequent Observations from Questionnaires in Order to Model Patient-Reported Outcomes (2019)
• Item Response Model Adaptation for Analyzing Data from Different Versions of Parkinson's Disease Rating Scales (2019)
• The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis (2019)
• The Integrated Glucose Insulin Minimal Model (2019)
• Translation between two models; Application with integrated glucose homeostasis models (2019)
• Variability Attribution for Automated Model Building (2019)
• Model-Based Conditional Weighted Residuals Analysis for Structural Model Assessment (2019)
• Comment on Jaki et al., A proposal for a new PhD level curriculum on quantitative methods for drug development. Pharmaceutical Statistics 17 (5):593-606, Sep/Oct 2018, DOI:10.1002/pst.1873 (2019)
• Open Systems Pharmacology Community-An Open Access, Open Source, Open Science Approach to Modeling and Simulation in Pharmaceutical Sciences (2019)
• Modeling Exposure-Driven Adverse Event Time Courses in Oncology Exemplified by Afatinib (2019)
• Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modelling (2019)
• A non-linear mixed effect model for innate immune response (2019)
• A Bounded Integer Model for Rating and Composite Scale Data (2019)
• A mechanism-based pharmacokinetic model of fenofibrate for explaining increased drug absorption after food consumption (2018)
• Dose-Exposure-Response Relationship of the Investigational Anti-Interleukin-13 Monoclonal Antibody Tralokinumab in Patients With Severe, Uncontrolled Asthma (2018)
• A Whole-Body Physiologically Based Pharmacokinetic Model for Colistin and Colistin Methanesulfonate in Rat (2018)
• Reduced and optimized trial designs for drugs described by a target mediated drug disposition model (2018)
• A Population Pharmacokinetic-Pharmacodynamic Model of Pegfilgrastim (2018)
• An exposure-response (ER) model relating nicotine plasma concentration to momentary craving across different nicotine replacement therapy (NRT) formulations (2018)
• Plasma and CSF pharmacokinetics of meropenem in neonates and young infants (2018)
• Suboptimal Antituberculosis Drug Concentrations and Outcomes in Small and HIV-Coinfected Children in India: Recommendations for Dose Modifications (2018)
• Model-based prediction of plasma concentration and enterohepatic circulation of total bile acids in humans (2018)
• Study Design Selection in Early Clinical Anti-Hyperglycemic Drug Development (2018)
• Model-Based Residual Post-Processing for Residual Model Identification (2018)
• Sample size for detection of drug effect using item level and total score models for Unified Parkinson's Disease Rating Scale data (2018)
• Population Pharmacokinetic and Pharmacodynamic Properties of Artesunate in Patients with Artemisinin Resistant Infections in Southern Myanmar (2018)
• Population Pharmacokinetics of Artemether, Dihydroartemisinin, and Lumefantrine in Rwandese Pregnant Women Treated for Uncomplicated Plasmodium falciparum Malaria (2018)
• The risk of febrile neutropenia in breast cancer patients following adjuvant chemotherapy is predicted by the time course of interleukin-6 and C-reactive protein by modelling. (2018)
• Pharmacometric analysis of the relationship between absolute lymphocyte count, and expanded disability status scale and relapse rate, efficacy end points, in multiple sclerosis trials (2018)
• Implicit and efficient handling of missing covariate information using full random effects modelling (2018)
• Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs (2018)
• A pharmacometric analysis of patient-reported outcomes in breast cancer patients through item response theory (2018)
• Evidence-Based Design of Fixed-Dose Combinations (2018)
• Comparison of Power, Prognosis, and Extrapolation Properties of Four Population Pharmacodynamic Models of HbA1c for Type 2 Diabetes (2018)
• Model-Based Interspecies Scaling of Glucose Homeostasis (2017)
• Second order Taylor expansion of likelihood-based models (2017)
• Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug resistant tuberculosis (2017)
• Impact of demographics and disease progression on the relationship between glucose and HbA1c (2017)
• Open innovation (2017)
• Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa (2017)
• An Automated Sampling Importance Resampling Procedure For Estimating Parameter Uncertainty (2017)
• An Automated Sampling Importance Resampling Procedure For Estimating Parameter Uncertainty (2017)
• Model averaging for robust assessment of QT prolongation by concentration-response analysis (2017)
• Implications for Drug Characterization in Glucose Tolerance Tests Without Insulin (2017)
• Modeling a Composite Score in Parkinson's Disease Using Item Response Theory (2017)
• Adjusted adaptive Lasso for covariate model-building in nonlinear mixed-effect pharmacokinetic models (2017)
• Comparison of diagnostics using model-based post-processing for fast automated model building (2017)
• Item Response Theory to Quantify Longitudinal Placebo and Paliperidone Effects on PANSS Scores in Schizophrenia (2017)
• Population Pharmacokinetic and Pharmacodynamic Modeling of Artemisinin Resistance in Southeast Asia (2017)
• Model-based prediction of myelosuppression and recovery based on frequent neutrophil monitoring (2017)
• Model Evaluation of Continuous Data Pharmacometric Models (2017)
• Application of Item Response Theory to Modeling of Expanded Disability Status Scale in Multiple Sclerosis (2017)
• Prediction of Improved Antimalarial Chemoprevention with Weekly Dosing of Dihydroartemisinin-Piperaquine (2017)
• Mathematical modelling of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 following ingestion of glucose (2017)
• A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin (2017)
• Population pharmacokinetics of cladribine in patients with multiple sclerosis (2017)
• A Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety in Metastatic Renal Cell Carcinoma Patients (2017)
• A Minimal Continuous-Time Markov Pharmacometric Model. (2017)
• Model Description Language (MDL) (2017)
• Modelling of mycobacterial load reveals bedaquiline's exposure-response relationship in patients with drug-resistant TB (2017)
• Evidence-based design of fixed-dose combinations (2017)
• Implementing Pharmacogenomics in Europe (2017)
• Differentiation between Parkinson's disease patients and SWEDDs based on the MDS-UPDRS (2017)
• Differentiation and prognosis of healthy subjects, swedds and parkinson's patients using a multi-dimensional item response theory model (2017)
• Population Pharmacokinetics to Model the Time-Varying Clearance of the PEGylated Asparaginase Oncaspar^® in Children with Acute Lymphoblastic Leukemia (2017)
• A diagnostic tool for population models using non-compartmental analysis (2016)
• Semi-mechanistic model describing gastric emptying and glucose absorption in healthy subjects and patients with type 2 diabetes (2016)
• Methods and strategies for assessing uncontrolled drug-drug interactions in population pharmacokinetic analyses (2016)
• BSA and ABCB1 polymorphism affect the pharmacokinetics of sunitinib and its active metabolite in Asian mRCC patients receiving an attenuated sunitinib dosing regimen (2016)
• Modeling the Disease Progression from Healthy to Overt Diabetes in ZDSD Rats (2016)
• Weight-HbA1c-Insulin-Glucose Model for Describing Disease Progression of Type 2 Diabetes (2016)
• Approaches for modeling within subject variability in pharmacometric count data analysis (2016)
• Improving The Estimation Of Parameter Uncertainty Distributions In Nonlinear Mixed Effects Models Using Sampling Importance Resampling (2016)
• A strategy for residual error modeling incorporating scedasticity of variance and distribution shape (2016)
• dOFV distributions (2016)
• Mechanism-Based Modeling of Gastric Emptying Rate and Gallbladder Emptying in Response to Caloric Intake (2016)
• Meta-analysis of Magnetic Marker Monitoring Data to Characterize the Movement of Single Unit Dosage Forms Though the Gastrointestinal Tract Under Fed and Fasting Conditions (2016)
• Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIs (2016)
• A Model-Based Longitudinal Meta-Analysis of FEV1 in Randomized COPD Trials (2016)
• Population Pharmacokinetics of Edoxaban in Patients with Non-Valvular Atrial Fibrillation in the ENGAGE AF-TIMI 48 Study, a Phase III Clinical Trial (2016)
• Methods for Predicting Diabetes Phase III Efficacy Outcome From Early Data (2016)
• Edoxaban Exposure-Response Analysis and Clinical Utility Index Assessment in Patients With Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism (2016)
• PK-PD Modeling of Individual Lesion FDG-PET Response to Predict Overall Survival in Patients With Sunitinib-treated Gastrointestinal Stromal Tumor (2016)
• Pharmacokinetic Interactions for Drugs with a Long Half-Life-Evidence for the Need of Model-Based Analysis (2016)
• Population Pharmacokinetics of Bedaquiline and Metabolite M2 in Patients With Drug-Resistant Tuberculosis (2016)
• A proof-of-principle example for identifying drug effect from a mechanistic model with a more parsimonious model (2016)
• Interspecies scaling of dynamic glucose and insulin using a mathematical model approach (2015)
• Characterization of dose-FEV1 response of tralokinumab, an investigational anti-IL13 monoclonal antibody in patients with uncontrolled asthma (2015)
• Evaluation of optimized bronchoalveolar lavage sampling designs for characterization of pulmonary drug distribution (2015)
• A mathematical disease progression model for the effect of diet and exercise in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study (FDPS) (2015)
• Pharmacokinetic and Pharmacokinetic/ Pharmacodynamic Modeling to Inform Optimal Dose of Vorapaxar (2015)
• Quantitative Model Diagrams (QMD) (2015)
• Population pharmacokinetics of edoxaban and its main metabolite in a dedicated renal impairment study (2015)
• Improved precision of exposure-response relationships by optimal dose-selection. Examples from studies of receptor occupancy using PET and dose finding for neuropathic pain treatment (2015)
• Estimation of drug receptor occupancy when non-displaceable binding differs between brain regions (2015)
• Population pharmacokinetics of edoxaban in patients with symptomatic deep-vein thrombosis and/or pulmonary embolism-the Hokusai-VTE phase 3 study (2015)
• Covariate analysis using item response theory modelling of expanded disability status scale (EDSS) (2015)
• Handling Underlying Discrete Variables with Mixed Hidden Markov Models in NONMEM (2015)
• Predicting Reductions in Chronic Obstructive Pulmonary Disease (COPD) Exacerbations from FEV1-A Model-Based Meta-Analysis of Literature Data from Controlled Randomized Clinical Trials (2015)
• Analyzing Patient-Reported Outcomes in Breast Cancer throughItem-Response Theory Pharmacometric Modeling (2015)
• Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug (2015)
• Pharmacometrics Markup Language (PharmML) (2015)
• Characterization of an in vivo concentration-effect relationship for piperaquine in malaria chemoprevention (2014)
• Optimal clinical trial design based on a dichotomous Markov-chain mixed-effect sleep model (2014)
• Concordance between criteria for covariate model building (2014)
• Evaluation of Bias, Precision, Robustness and Runtime for Estimation Methods in NONMEM 7 (2014)
• Simultaneous Exposure-Response Modeling of ACR20, ACR50, and ACR70 Improvement Scores in Rheumatoid Arthritis Patients With Certolizumab Pegol (2014)
• Methods for Predicting Diabetes Phase III Efficacy Outcome From Early Data (2014)
• Characterization of Endogenous G-CSF and the Inverse Correlation to Chemotherapy-Induced Neutropenia in Patients with Breast Cancer Using Population Modeling (2014)
• A linearization approach for the model-based analysis of combined aggregate and individual patient data (2014)
• Impact of Lopinavir-Ritonavir or Nevirapine on Bedaquiline Exposures and Potential Implications for Patients with Tuberculosis-HIV Coinfection (2014)
• Use of a linearization approximation facilitating stochastic model building (2014)
• Improved Utilization of ADAS-cog Assessment Data through Item Response Theory based Pharmacometric Modeling (2014)
• Whole Body Physiologically-Based Pharmacokinetic Model for Colistin and Colistimethate Sodium (CMS) in Six Different Species (2013)
• A Time-to-Event Pharmacodynamic Model Describing Treatment Response in Patients with Pulmonary Tuberculosis Using Days to Positivity in Automated Liquid Mycobacterial Culture (2013)
• Identification of the primary mechanism of action of an insulin secretagogue from meal test data in healthy volunteers based on an integrated glucose-insulin model (2013)
• A Model Predicting Penetration of Rifampicin from Plasma to Epithelial Lining Fluid and Alveolar Cells (2013)
• Population pharmacokinetics of daptomycin in patients affected by severe Gram-positive infections (2013)
• Simultaneous optimal experimental design for in vitro binding parameter estimation (2013)
• A time-to-event model for acute rejections in paediatric renal transplant recipients treated with ciclosporin A (2013)
• PKPD Modeling of VEGF, sVEGFR-2, sVEGFR-3, and sKIT as Predictors of Tumor Dynamics and Overall Survival Following Sunitinib Treatment in GIST (2013)
• PKPD Modeling of Predictors for Adverse Effects and Overall Survival in Sunitinib-Treated Patients With GIST (2013)
• Drug and disease model resources (2013)
• Comparison of Methods for Handling Missing Covariate Data (2013)
• Multiple Imputation of Missing Covariates in NONMEM and Evaluation of the Method's Sensitivity to eta-Shrinkage (2013)
• Comparisons of Analysis Methods for Proof-of-Concept Trials (2013)
• Best practices in population modeling should always be evolving (2013)
• Modeling and Simulation Workbench for NONMEM (2013)
• A Model-Based Approach to Predict Longitudinal HbA1c, Using Early Phase Glucose Data From Type 2 Diabetes Mellitus Patients After Anti-Diabetic Treatment (2013)
• A positron emission tomography study in healthy volunteers to estimate mGluR5 receptor occupancy of AZD2066-Estimating occupancy in the absence of a reference region (2013)
• A semi-mechanistic model of the relationship between average glucose and HbA1c in healthy and diabetic subjects (2013)
• Modeling and simulation to optimize the design and analysis of confirmatory trials, characterize risk-benefit, and support label claims (2013)
• Current Use and Developments Needed for Optimal Design in Pharmacometrics (2013)
• ADOPT (A Dynamic HbA(1c) EndpOint Prediction Tool) (2013)
• Longitudinal Modeling of the Relationship Between Mean Plasma Glucose and HbA1c Following Antidiabetic Treatments (2013)
• Assessment of glycemic response to an oral glucokinase activator in a proof of concept study (2013)
• Model-Based Estimates of the Effects of Efavirenz on Bedaquiline Pharmacokinetics and Suggested Dose Adjustments for Patients Coinfected with HIV and Tuberculosis (2013)
• Optimizing disease progression study designs for drug effect discrimination (2013)
• Predicting Baseline ADAS-cog Scores from Screening Information using Item Response Theory and Full Random Effect Covariate Modeling (2013)
• Pharmacometric Modeling of Clinical ADAS-cog Assessment Data using Item Response Theory (2013)
• Benefits of an Item Response Theory Based Analysis of ADAS-cog Assessments (2013)
• A Nonlinear Mixed Effects Pharmacokinetic Model for Dapagliflozin and Dapagliflozin 3-O-glucuronide in Renal or Hepatic Impairment (2013)
• Model-based evaluation of the pharmacokinetic differences between adults and children for lopinavir and ritonavir in combination with rifampicin (2013)
• Modeling longitudinal daily seizure frequency data from pregabalin add-on treatment (2012)
• A semi-mechanistic modeling strategy for characterization of regional absorption properties and prospective prediction of plasma concentrations following administration of new modified release formulations (2012)
• A Semi-mechanistic Modeling Strategy to Link In Vitro and In Vivo Drug Release for Modified Release Formulations (2012)
• Analysis of exposure-response of CI-945 in patients with epilepsy (2012)
• Integrated Population Pharmacokinetic Analysis of Voriconazole in Children, Adolescents, and Adults (2012)
• Pharmacokinetic-Pharmacodynamic Assessment of the Interrelationships Between Tesaglitazar Exposure and Renal Function in Patients With Type 2 Diabetes Mellitus (2012)
• Application of the Optimal Design Approach to Improve a Pretransplant Drug Dose Finding Design for Ciclosporin (2012)
• A mechanism-Based Approach for Absorption Modeling (2012)
• Identification of the Mechanism of Action of a Glucokinase Activator From Oral Glucose Tolerance Test Data in Type 2 Diabetic Patients Based on an Integrated Glucose-Insulin Model (2012)
• Standard Error of Empirical Bayes Estimate in NONMEM (R) VI (2012)
• Letter to the editor regarding (2012)
• Non-linear mixed effects modelling of positron emission tomography data for simultaneous estimation of radioligand kinetics and occupancy in healthy volunteers (2012)
• Evaluation of IPPSE, an alternative method for sequential population PKPD analysis (2012)
• Modeling of red blood cell life-spans in hematologically normal populations (2012)
• Ethically Attractive Dose-Finding Designs for Drugs With a Narrow Therapeutic Index (2012)
• Serial correlation in optimal design for nonlinear mixed effects models (2012)
• PopED (2012)
• Likert Pain Scores Modeling (2012)
• Performance comparison of various maximum likelihood nonlinear mixed-effects estimation methods for dose-response models (2012)
• A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model (2012)
• Integration of data from multiple sources for simultaneous modelling analysis (2012)
• Population Pharmacokinetics of Busulfan in Children (2012)
• Influence of CYP2B6 516G > T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children (2012)
• Rapid Sample Size Calculations for a Defined Likelihood Ratio Test-Based Power in Mixed-Effects Models (2012)
• Shrinkage in Nonlinear Mixed-Effects Population Models (2012)
• Model-based approach to dose optimization of lopinavir/ritonavir when co-administered with rifampicin (2012)
• Population Pharmacokinetic Model for Adherence Evaluation Using Lamivudine Concentration Monitoring (2012)
• Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children (2012)
• Two bootstrapping routines for obtaining imprecision estimates for nonparametric parameter distributions in nonlinear mixed effects models (2011)
• Modeling of 24-Hour Glucose and Insulin Profiles of Patients With Type 2 Diabetes (2011)
• A Population Pharmacokinetic/Pharmacodynamic Model of Methotrexate and Mucositis Scores in Osteosarcoma (2011)
• Performance of three estimation methods in repeated time-to-event modeling (2011)
• A Fast Method for Testing Covariates in Population PK/PD Models (2011)
• Modeling sleep data for a new drug in development using Markov mixed-effects models (2011)
• Transient Lower Esophageal Sphincter Relaxations PKPD Modeling (2011)
• Population pharmacokinetics of busulfan in children (2011)
• Population pharmacokinetics of tacrolimus in pediatric liver transplantation (2011)
• A pharmacokinetic-pharmacodynamic model for duodenal levodopa infusion (2011)
• Multinomial logistic estimation of Markov-chain models for modeling sleep architecture in primary insomnia patients (2010)
• A two-compartment effect site model describes the bispectral index after different rates of propofol infusion (2010)
• Incorporating Physiological and Biochemical Mechanisms into Pharmacokinetic-Pharmacodynamic Models (2010)
• Methodological Comparison of In Vitro Binding Parameter Estimation (2010)
• Long-Term Changes in Cyclosporine Pharmacokinetics After Renal Transplantation in Children (2010)
• A Semi-Mechanistic Model of CP-690,550-Induced Reduction in Neutrophil Counts in Patients With Rheumatoid Arthritis (2010)
• Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression (2010)
• Modeling Disease Progression in Acute Stroke Using Clinical Assessment Scales (2010)
• Evaluation of management of hypertension in response to the receptor tyrosine kinase inhibitor, E7080 (2010)
• A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080 (2010)
• Comparison of the agonist-antagonist interaction model and the pool model for the effect of remoxipride on prolactin (2010)
• Transforming parts of a differential equations system to difference equations as a method for run-time savings in NONMEM (2010)
• Approaches to simultaneous analysis of frequency and severity of symptoms (2010)
• A Model for Glucose, Insulin, and Beta-Cell Dynamics in Subjects With Insulin Resistance and Patients With Type 2 Diabetes (2010)
• An integrated glucose-insulin model to describe oral glucose tolerance test data in healthy volunteers (2010)
• An Integrated Model for the Glucose-Insulin System (2010)
• Modelling the genesis and treatment of cancer (2010)
• Model-Based Neutrophil-Guided Dose Adaptation in Chemotherapy (2010)
• Rescue therapy with high-dose oral phenobarbitone loading for refractory status epilepticus (2010)
• Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents (2010)
• Evaluation of the Nonparametric Estimation Method in NONMEM VI: Application to Real Data (2009)
• Handling data below the limit of quantification in mixed effect models. (2009)
• Mechanistic modeling of a magnetic marker monitoring study linking gastrointestinal tablet transit, in vivo drug release, and pharmacokinetics (2009)
• An agonist-antagonist interaction model for prolactin release following risperidone and paliperidone treatment (2009)
• Modeling and Simulation of the Time Course of Asenapine Exposure Response and Dropout Patterns in Acute Schizophrenia (2009)
• Trial treatment length optimization with an emphasis on disease progression studies (2009)
• Modeling subpopulations with the $MIXTURE subroutine in NONMEM (2009)
• A population pharmacokinetic model of gabapentin developed in nonparametric adaptive grid and nonlinear mixed effects modeling (2009)
• Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies (2009)
• A pharmacodynamic Markov mixed-effects model for determining the effect of exposure to certolizumab pegol on the ACR20 score in patients with rheumatoid arthritis (2009)
• A Pharmacodynamic Markov Mixed-Effects Model for Determining the Effect of Exposure to Certolizumab Pegol on the ACR20 Score in Patients With Rheumatoid Arthritis (2009)
• The time course of body temperature, serum amyloid A protein, C-reactive protein and interleukin-6 in patients with bacterial infection during the initial 3 days of antibiotic therapy (2009)
• The influence of underlying assumptions on evaluating the relative merits of concentration-controlled and dose-controlled trials (2009)
• Comparison of dose-finding designs for narrow-therapeutic-index drugs (2009)
• Simultaneous optimal experimental design on dose and sample times (2009)
• Semiparametric Distributions with Estimated Shape Parameters (2009)
• Performance in population models for count data, part I: maximum likelihood approximations. (2009)
• Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions (2009)
• Evaluation of an Extended Grid Method for Estimation Using Nonparametric Distributions (2009)
• Evaluation of the Nonparametric Estimation Method in NONMEM VI (2009)
• The impact of misspecification of residual error or correlation structure on the type I error rate for covariate inclusion (2009)
• Optimization of the intravenous glucose tolerance test in T2DM patients using optimal experimental design (2009)
• Modelling overdispersion and Markovian features in count data. (2009)
• A tool for neutrophil guided dose adaptation in chemotherapy (2009)
• Approaches to handling pharmacodynamic baseline responses (2008)
• A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials (2008)
• Models for plasma glucose, HbA1c, and hemoglobin interrelationships in patients with type 2 diabetes following tesaglitazar treatment (2008)
• Mechanistic modelling of tesaglitazar pharmacokinetic data in subjects with various degrees of renal function (2008)
• Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function (2008)
• Comparison of proportional odds and differential odds models for mixed-effects analysis of categorical data (2008)
• Pharmacodynamics of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe substrates midazolam, caffeine, and digoxin (2008)
• The use of clinical irrelevance criteria in covariate model building with application to dofetilide pharmacokinetic data (2008)
• Population Pharmacokinetics of Rifampin in Pulmonary Tuberculosis Patients Including a Semi-mechanistic Model to Describe Variable Absorption (2008)
• Developmental pharmacokinetics of ciclosporin (2007)
• Time for quantitative clinical pharmacology (2007)
• Conditional weighted residuals (CWRES) (2007)
• An integrated glucose-insulin model to describe oral glucose tolerance test data in type 2 diabetics (2007)
• Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients (2007)
• Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients (2007)
• Randomized exposure-controlled trials (2007)
• Diagnosing Model Diagnostics (2007)
• Linking preclinical and clinical whole-body physiologically based pharmacokinetic models with prior distributions in NONMEM (2007)
• An integrated model for the effect of budesonide on ACTH and cortisol in healthy volunteers (2007)
• Optimal adaptive design in clinical drug development (2007)
• Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments (2007)
• Pharmacodynamic model of interleukin-21 effects on red blood cells in cynomolgus monkeys. (2007)
• Modeling of in vitro drug activity and prediction of clinical outcome in acute myeloid leukemia (2007)
• Implementation of a Transit Compartment Model for Describing Drug Absorption in Pharmacokinetic Studies (2007)
• An integrated model for glucose and insulin regulation in healthy volunteers and type 2 diabetic patients following intravenous glucose provocations (2007)
• Population pharmacokinetic/pharmacodynamic (PK/PD) modelling of the hypothalamic-pituitary-gonadal axis following treatment with GnRH analogues (2007)
• Influence of CYP3A4 Inhibition on the Steady-State Pharmacokinetics of Imatinib (2007)
• Population pharmacokinetics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, in atrial fibrillation patients receiving long-term anticoagulation therapy (2006)
• CHS 828 kill tumour cells by inhibiting the nuclear factor-kappa B translocation but unlikely through down-regulation of proteasome (2006)
• Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification (2006)
• A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy. (2006)
• Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy. (2006)
• CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors (2006)
• A mechanism-based integrated pharmacokinetic enzyme model describing the time course and magnitude of phenobarbital-mediated enzyme induction in the rat. (2006)
• A mechanism-based integrated pharmacokinetic enzyme model describing the time course and magnitude of phenobarbital-mediated enzyme induction in the rat (2006)
• Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients. (2006)
• A population pharmacokinetic model for cefuroxime using cystatin C as a marker of renal function (2006)
• Application of a combined effect compartment and binding model for gastric acid inhibition of AR-HO47108 (2006)
• Pharmacokinetics of Desmopressin Administrated as an Oral Lyophilisate Dosage Form in Children With Primary Nocturnal Enuresis and Healthy Adults (2006)
• Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis. (2005)
• Pharmacokinetics of ximelagatran and relationship to clinical response in acute vein thrombosis (2005)
• Pharmacokinetic-pharmacodynamic modelling of the schedule-dependent effect of the anti-cancer agent CHS 828 in a rat hollow fibre model. (2005)
• Pharmacokinetic-Pharmacodynamic modelling of the schedule-dependent effect of the anti-cancer agent CHS 828 in a rat hollow fibre model (2005)
• A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first-pass hepatic extraction. (2005)
• Cytotoxic activity of a new paclitaxel formulation, Pacliex, in vitro and in vivo (2005)
• Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. (2005)
• Population pharmacokinetic modelling and estimation of dosing strategy for NXY-059, a nitrone being developed for stroke. (2005)
• Population pharmacokinetic modelling and estimation of dosing strategy for NXY-059, a nitrone being developed for stroke (2005)
• Estimation of dosing strategies aiming at maximizing utility or responder probability, using oxybutynin as an example drug. (2005)
• Estimation of dosing strategies aiming at maximizing utility or responder probability, using oxybutynin as an example drug (2005)
• Pharmacokinetic/pharmacodynamic modelling in oncological drug development. (2005)
• Application of population pharmacokinetics to cladribine. (2005)
• Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients. (2005)
• Model describing the relations between pharmacokinetics and hematological toxicity of the epirubicin-docetaxel regimen in breast cancer (2005)
• Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam. (2005)
• Modelling a spontaneously reported side effect by use of a Markov mixed-effects model. (2005)
• Estimating bias in population parameters for some models for repeated measures ordinal data using NONMEM or NLMIXED (2004)
• Factors influencing the choice of optimal individualized dosing strategies targeting a drug concentration or effect (2004)
• The back-step method (2004)
• Pharmacokinetic/pharmacodynamic models for the depletion of Vβ5.2/5.3 T cells by the monoclonal antibody ATM-027 in patients with multiple sclerosis, as measured by FACS (2004)
• The dosing solution influence on the pharmacokinetics of degarelix, a new GnRH antagonist, after s.c. administration to beagle dogs. (2003)
• Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran (2003)
• Mechanistic models for myelosuppression (2003)
• Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients (2003)
• Intravenously administered digoxin in patients with acute atrial fibrillation (2003)
• Population pharmacokinetics of levosimendan in patients with congestive heart failure (2003)
• A rational approach for selection of optimal covariate-based dosing strategies (2003)
• A rational approach for selection of optimal covariate-based dosing strategies (2003)
• Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability (2003)
• Variable Expression of CYP and Pgp Genes in the Human Small Intestine (2003)
• Comparison of cytotoxicity of 2-chloro- 2'-arabino-fluoro-2'-deoxyadenosine (clofarabine) with cladribine in mononuclear cells from patients with acute myeloid and chronic lymphocytic leukemia (2003)
• Irinotecan pathway genotype analysis to predict pharmacokinetics (2003)
• Population pharmacokinetics of clomethiazole and its effect on the natural course of sedation in acute stroke patients (2003)
• Population pharmacokinetics of clomethiazole and its effect on the natural course of sedation in acute stroke patients (2003)
• Model of Chemotherapy-Induced Myelosuppression With Parameter Consistency Across Drugs (2002)
• Model of chemotherapy-induced myelosuppression with parameter consistency across drugs (2002)
• A Phase I Study of CHS 828 in Patients with Solid Tumor Malignancy (2002)
• Population pharmacokinetic and pharmacodynamic modelling of artemisinin and mefloquine enantiomers in patients with falciparum malaria. (2002)
• Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis. (2002)
• Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea (2002)
• Gastric acid secretion in the dog (2002)
• Population modelling of the effect of inogatran, at thrombin inhibitor, on ex vivo coagulation time (APTT) in healthy subjects and patients with coronary artery disease (2001)
• A hollow fiber model for in vitro studies of cytotoxic compounds (2001)
• Model for time dependency of the cytotoxic effect of CHS 828 in vitro suggests two different mechanisms of action (2001)
• Mechanism-based pharmacokinetic model for paclitaxel (2001)
• Pharmacodynamic modelling of reversible gastric acid pump inhibition in dog and man (2001)
• Determination of drug effect on tumour cells, host animal toxicity and drug pharmacokinetics in a hollow-fibre model in rats (2000)
• Haematological toxicity following different dosing schedules of 5-fluorouracil and epirubicin in rats (2000)
• A turnover model of irreversible inhibition of gastric acid secretion by omeprazole in the dog (2000)
• The pharmacokinetic modelling of GI198745 (dutasteride), a compound with parallel linear and nonlinear elimination (1999)
• Lactational exposure and neonatal kinetics of methylmercury and inorganic mercury in mice. (1999)
• Kinetics of methylmercury and inorganic mercury in lactating and nonlactating mice. (1998)
• Toxicokinetics of lead in lactating and nonlactating mice. (1996)
• Kinetic observations in neonatal mice exposed to lead via milk. (1996)
• Relationship between factor VIII activity, bleeds and individual characteristics in severe hemophilia A patients
• Predictive performance of internal and external validation procedures
• A novel covariate search method intended for PKPD models with nonparametric parameter distributions
• Evaluation of model-integrated evidence approaches for pharmacokinetic bioequivalence studies using model averaging methods
• Characterization of Anti-Drug Antibody Dynamics Using a Bivariate Mixed Hidden-Markov Model
• Comparative Analysis of Pharmacoeconomic and Pharmacometric Modeling in the Cost-Effectiveness Evaluation of Sunitinib Therapy with Therapeutic Drug Monitoring for Gastrointestinal Stromal Tumors
• Extension of individual model averaging assessments to unbalanced designs and dose-response.
• Assessment of non-linear mixed effect model-based approaches to test for drug effect using simulated data: type I error and power properties.
• Development and comparison of model-integrated evidence approaches for bioequivalence studies with pharmacokinetic endpoints
• Utility of ecarin clotting time, an ex vivo coagulation test, for pharmacokinetic analysis of the direct thrombin inhibitor melagatran
• Ximelagatran in extended secondary prevention of venous thromboembolism: Pharmacokinetics, pharmacodynamics and relationships to clinical events
• Multinomial Markov-chain model of sleep architecture in Phase Advanced Subjects
• Pharmacokinetic-pharmacodynamic modeling of the schedule-dependent effect of CHS 828 in a rat hollow fiber model
• Does the novel anticancer agent CHS 828 induces tumor cell death by inhibiting the transcription factor NF-kB translocation through down regulation of the proteasome?
• Population Pharmacokinetic Model for Cremophor EL
• Evaluating the evaluations: resampling methods for determining model appropriateness in pharmacometric data analysis
• Expression of UDP-Glucuronosyltransferase Genes (UGTs) in Human Duodenum
• The influence of second-line immuno-therapies on the survival outcome of first-line non-small cell lung cancer atezolizumab IMpower131 study: An application of multistate modeling
• Pharmacodynamics of enzyme induction attributable to carbamazepine treatment using midazolam, caffeine and digoxin as probe substrates
• A mechanistic model describing the impact of carbamazepine on the pharmacokinetics of clomethiazole and its metabolite NLA-715
• Modeling of mycobacterial load reveals bedaquiline’s exposure-response relationship in patients with drug-resistant tuberculosis
• Pharmacodynamic interaction of bedaquiline and delamanid co-administration on QTcF interval prolongation
• Challenges and potential of optimal design in late phase clinical trials through application in Alzheimer’s disease
• Individualization of Cefuroxime Dosage using Pharmacodynamic targets, MIC distributions and Minimization of a Risk Function
• The time course of the biomarkers body temperature, serum amyloid A protein (SAA), C-reactive protein (CRP) and interleukin- (IL) 6 during initial treatment with cefuroxime in patients with bacterial infections
• Optimal Design Applied to Hematological Toxicity-Induced Anticancer Treatment
• Population pharmacokinetics of tacrolimus in paediatric liver transplant recipients
• Item Response Theory-Informed Total Score Analysis
• Comparing the differential drug effect model to the proportional odds model
• Application of a combined effect-compartment and binding model for gastric acid inhibition of AR-HO47108, a reversible gastric acid proton pump inhibitor, and its active metabolite AR-HO47116, in the dog